

# Renata Mikolajczak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5689692/publications.pdf>

Version: 2024-02-01

90  
papers

1,755  
citations

257450

24  
h-index

302126

39  
g-index

95  
all docs

95  
docs citations

95  
times ranked

1744  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 935-936.	6.4	18
2	Development and validation of the HPLC method for quality control of radiolabelled DOTA-TATE and DOTA-TOC preparations. <i>Nuclear Medicine and Biology</i> , 2021, 93, 63-73.	0.6	4
3	Radionuclide generators. , 2021, , .		1
4	In memoriam " Prof. Anna Celler. <i>Nuclear Medicine Review</i> , 2021, 24, 37-39.	0.5	0
5	SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers. <i>Pharmaceuticals</i> , 2021, 14, 300.	3.8	5
6	PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2731.	4.1	7
7	An approach towards reverse generator system for 99mTc separation from LSA 99Mo. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, S97.	0.6	0
8	Studies on the novel scandium-47 labelled PSMA inhibitor targeting ligand. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, S102.	0.6	0
9	Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy"Part II. Toxicity, Pharmacokinetics and Biodistribution. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5702.	4.1	8
10	Clickable Radiocomplexes With Trivalent Radiometals for Cancer Theranostics: In vitro and in vivo Studies. <i>Frontiers in Medicine</i> , 2021, 8, 647379.	2.6	5
11	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 31.	3.9	0
12	IAEA Activities on 67Cu, 186Re, 47Sc Theranostic Radionuclides and Radiopharmaceuticals. <i>Current Radiopharmaceuticals</i> , 2021, 14, 306-314.	0.8	13
13	Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation"Preclinical Assessment of Two Optimized Candidates. <i>Pharmaceuticals</i> , 2021, 14, 19.	3.8	8
14	[99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes. <i>Cancers</i> , 2021, 13, 5093.	3.7	14
15	Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals. <i>Cancers</i> , 2021, 13, 5776.	3.7	10
16	Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys40(AhxHYNIC-[99mTc])/EDDA]NH2]-Exendin-4 over Conventional Imaging Modalities for Localization of Insulinoma. <i>Molecular Imaging and Biology</i> , 2020, 22, 165-172.	2.6	9
17	Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 922-933.	6.4	31
18	Impact of DOTA-Chelators on the Antitumor Activity of <sup>177</sup> Lu-DOTA-Rituximab Preparations in Lymphoma Tumor-Bearing Mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 558-562.	1.0	4

#	ARTICLE	IF	CITATIONS
19	Comparison of separation methods for <sup>47</sup> Ca/ <sup>47</sup> Sc radionuclide generator. Applied Radiation and Isotopes, 2019, 151, 140-144.	1.5	5
20	Radiometals for imaging and theranostics, current production, and future perspectives. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 615-634.	1.0	49
21	Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 673-683.	1.0	31
22	Improved procedures of Sc(OH) <sub>3</sub> precipitation and UTEVA extraction for <sup>44</sup> Sc separation. Nuclear Medicine Review, 2019, 22, 56-59.	0.5	1
23	Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor. EJNMMI Research, 2018, 8, 33.	2.5	9
24	A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma " GRAN-T-MTC " a multicenter phase I study. Polish Archives of Internal Medicine, 2018, 128, 791-795.	0.4	16
25	Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of Lu- and Y-Rituximab in Xenografted Mice. Iranian Journal of Pharmaceutical Research, 2018, 17, 1201-1208.	0.5	3
26	Manufacturing and characterization of molybdenum pellets used as targets for <sup>99m</sup> Tc production in cyclotron. Applied Radiation and Isotopes, 2017, 124, 124-131.	1.5	6
27	Long-term results and tolerability of tandem peptide receptor radionuclide therapy with <sup>90</sup> Y/ <sup>177</sup> Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Annals of Nuclear Medicine, 2017, 31, 347-356.	2.2	47
28	<sup>177</sup> Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation. Molecular Pharmaceutics, 2017, 14, 3045-3058.	4.6	11
29	New synthesis route of active substance d,l-HMPAO for preparation Technetium Tc <sup>99m</sup> Exametazime. Nuclear Medicine Review, 2017, 20, 88-94.	0.5	2
30	Application of AnaLig resin for <sup>99m</sup> Tc separation from <sup>100</sup> Mo target irradiated in cyclotron. Applied Radiation and Isotopes, 2016, 113, 75-78.	1.5	9
31	A one-step automated synthesis of the dopamine transporter ligand [ <sup>18</sup> F]FECNT from the chlorinated precursor. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 82-86.	1.0	0
32	Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with <sup>111</sup> In-CP04 in medullary thyroid carcinoma patients. European Journal of Pharmaceutical Sciences, 2016, 91, 236-242.	4.0	43
33	From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. European Journal of Pharmaceutical Sciences, 2016, 85, 1-9.	4.0	29
34	<sup>99m</sup> Tc Labeled Glucagon-Like Peptide-1-Analogue ( <sup>99m</sup> Tc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma. PLoS ONE, 2016, 11, e0160714.	2.5	30
35	Rak rdzeniasty tarczycy " badanie PET/CT ze znakowanymi <sup>68</sup> Ga analogami gastryny i somatostatyny. Endokrynologia Polska, 2016, 67, 68-71.	1.0	15
36	Influence of PET/CT <sup>68</sup> Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with <sup>99m</sup> Tc-EDDA/HYNIC-TOC SPECT. Nuclear Medicine Review, 2016, 19, 88-92.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Oxidation of methionine " is it limiting the diagnostic properties of <sup>99m</sup> Tc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?. Nuclear Medicine Review, 2016, 19, 104-110.	0.5	10
38	Radiopharmaceuticals for somatostatin receptor imaging. Nuclear Medicine Review, 2016, 19, 126-132.	0.5	33
39	Standardization of Procedures for the Preparation of <sup>177</sup> Lu- and <sup>90</sup> Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation. Current Radiopharmaceuticals, 2015, 8, 62-68.	0.8	10
40	Chemistry and bifunctional chelating agents for binding <sup>177</sup> Lu. Current Radiopharmaceuticals, 2015, 8, 86-94.	0.8	19
41	Lu-177-Labeled Zirconia Particles for Radiation Synovectomy. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 433-438.	1.0	8
42	The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y. Nuclear Medicine Review, 2015, 18, 51-55.	0.5	8
43	Studies on the separation of <sup>99m</sup> Tc from large excess of molybdenum. Nuclear Medicine Review, 2015, 18, 65-69.	0.5	7
44	Synthesis of novel halo and tosyloxy nortropane derivatives as efficient precursors for the one-step synthesis of the dopamine transporter PET ligand [ <sup>18</sup> F]FECNT. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 148-157.	1.0	6
45	Evaluation of dead-time corrections for post-radionuclide-therapy <sup>177</sup> Lu quantitative imaging with low-energy high-resolution collimators. Nuclear Medicine Communications, 2014, 35, 73-87.	1.1	11
46	A Frequency and Semiquantitative Analysis of Pathological <sup>68</sup> Ga DOTATATE PET/CT Uptake by Primary Site-Dependent Neuroendocrine Tumor Metastasis. Clinical Nuclear Medicine, 2014, 39, 855-861.	1.3	13
47	Initial Study of Radiological and Clinical Efficacy Radioembolization Using <sup>188</sup> Re-Human Serum Albumin (HSA) Microspheres in Patients with Progressive, Unresectable Primary or Secondary Liver Cancers. Medical Science Monitor, 2014, 20, 1353-1362.	1.1	22
48	Glucagon-like peptide-1 receptor imaging with [Lys <sup>40</sup> (Ahx-HYNIC- <sup>99m</sup> Tc/EDDA)NH <sub>2</sub> ]-exendin-4 for the detection of insulinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 524-531.	6.4	96
49	Determination of <sup>90</sup> Sr traces in medical <sup>90</sup> Y after separation on DGA column. Talanta, 2013, 114, 1-4.	5.5	7
50	Glucagon-Like Peptide-1 Receptor Imaging with [Lys <sup>40</sup> (Ahx-HYNIC- <sup>99m</sup> Tc/EDDA)NH <sub>2</sub> ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report. International Journal of Endocrinology, 2013, 2013, 1-6.	1.5	23
51	Polish Experience in Peptide Receptor Radionuclide Therapy. Recent Results in Cancer Research, 2013, 194, 467-478.	1.8	9
52	Semiquantitative Analysis and Characterization of Physiological Biodistribution of <sup>68</sup> Ga-DOTA-TATE PET/CT. Clinical Nuclear Medicine, 2012, 37, 1052-1057.	1.3	43
53	Repeated cycles of peptide receptor radionuclide therapy (PRRT) " Results and side-effects of the radioisotope <sup>90</sup> Y-DOTA TATE, <sup>177</sup> Lu-DOTA TATE or <sup>90</sup> Y/ <sup>177</sup> Lu-DOTA TATE therapy in patients with disseminated NET. Radiotherapy and Oncology, 2012, 102, 45-50.	0.6	39
54	<sup>44</sup> Sc-DOTA-BN[2-14]NH <sub>2</sub> in comparison to <sup>68</sup> Ga-DOTA-BN[2-14]NH <sub>2</sub> in pre-clinical investigation. Is <sup>44</sup> Sc a potential radionuclide for PET?. Applied Radiation and Isotopes, 2012, 70, 2669-2676.	1.5	49

#	ARTICLE	IF	CITATIONS
55	Imaging of inflamed carotid artery atherosclerotic plaques with the use of <sup>99m</sup> Tc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 673-682.	6.4	7
56	Recombinant fragment of an antibody tailored for direct radioiodination. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 52-56.	1.0	0
57	Radiopharmaceuticals in cardiology. <i>Nuclear Medicine Review</i> , 2012, 15, 39-45.	0.5	3
58	Radiopharmaceuticals in cardiology. <i>Nuclear Medicine Review</i> , 2012, 15, 39-45.	0.5	6
59	Dosimetry of exendin-4 based radiotracer for glucagonlike peptide-1 receptor imaging: an initial report. <i>Journal of Physics: Conference Series</i> , 2011, 317, 012011.	0.4	2
60	Patient-Specific Radiation Dosimetry of <sup>99m</sup> Tc-HYNIC-Tyr <sup>3</sup> -Octreotide in Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1474-1481.	5.0	37
61	Clinical results of radionuclide therapy of neuroendocrine tumours with <sup>90</sup> Y-DOTATATE and tandem <sup>90</sup> Y/ <sup>177</sup> Lu-DOTATATE: which is a better therapy option?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1788-1797.	6.4	211
62	Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1669-1674.	6.4	89
63	The penetration of topically applied ointment containing hyaluronic acid in rabbit tissues. <i>Polish Journal of Veterinary Sciences</i> , 2011, 14, 621-7.	0.2	4
64	Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?. <i>Nuclear Medicine Review</i> , 2011, 14, 73-78.	0.5	10
65	Comparison of receptor affinity of natSc-DOTA-TATE versus natGa-DOTA-TATE. <i>Nuclear Medicine Review</i> , 2011, 14, 85-89.	0.5	26
66	Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1049-1062.	6.4	113
67	Investigation of <sup>99m</sup> Tc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide. <i>Nuclear Medicine and Biology</i> , 2010, 37, 795-803.	0.6	11
68	Identification of Inflamed Atherosclerotic Plaque using <sup>123</sup> I-Labeled Interleukin-2 Scintigraphy in High-Risk Peritoneal Dialysis Patients: A Pilot Study. <i>Peritoneal Dialysis International</i> , 2009, 29, 568-574.	2.3	11
69	Comparative study on DOTA-derivatized bombesin analog labeled with <sup>90</sup> Y and <sup>177</sup> Lu: in vitro and in vivo evaluation. <i>Nuclear Medicine and Biology</i> , 2009, 36, 591-603.	0.6	30
70	Investigation of the <sup>188</sup> Re Eluate Suitability for Medical Purposes by Labeling a Bombesin Analog (BN1.1). <i>Current Radiopharmaceuticals</i> , 2009, 2, 295-303.	0.8	1
71	Identification of inflamed atherosclerotic plaque using <sup>123</sup> I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study. <i>Peritoneal Dialysis International</i> , 2009, 29, 568-74.	2.3	5
72	Initial Direct Comparison of <sup>99m</sup> Tc-TOC and <sup>99m</sup> Tc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1060-1065.	5.0	55

#	ARTICLE	IF	CITATIONS
73	Two Peptide Receptor Ligands $^{99m}\text{Tc}$ -EDDA/HYNIC-Tyr <sup>3</sup> -Octreotide and $^{99m}\text{Tc}$ -EDDA/HYNIC-D <sup>1</sup> -Glu-Octagastrin for Scintigraphy of Medullary Thyroid Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 613-628.	1.0	13
74	Somatostatin receptor scintigraphy using $^{99m}\text{Tc}$ -EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1635-1645.	6.4	45
75	Short Communication: Semiquantitative Assessment of $^{99m}\text{Tc}$ -EDDA/HYNIC-TOC Scintigraphy in Differentiation of Solitary Pulmonary Nodules – a Complementary Role to Visual Analysis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 61-67.	1.0	4
76	Differential diagnosis of solitary pulmonary nodules based on $^{99m}\text{Tc}$ -EDDA/HYNIC-TOC scintigraphy: the effect of tumour size on the optimal method of image assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1041-1047.	6.4	13
77	Kit with technetium- $^{99m}$ labelled antimicrobial peptide UBI 29-41 for specific infection detection. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2005, 48, 683-691.	1.0	14
78	Activation cross sections for reactions induced by 14 MeV neutrons on natural tin and enriched $^{112}\text{Sn}$ targets with reference to $^{111}\text{In}$ production via radioisotope generator $^{112}\text{Sn}(n, 2n)^{111}\text{Sn} \rightarrow ^{111}\text{In}$ . <i>Radiochimica Acta</i> , 2005, 93, 311-326.	1.2	39
79	$^{99m}\text{Tc}$ -EDDA/HYNIC-TOC in the Management of Medullary Thyroid Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 211-217.	1.0	24
80	Clinical Usefulness of $^{99m}\text{Tc}$ -EDDA/HYNIC-TOC Scintigraphy in Oncological Diagnostics: A Pilot Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 261-270.	1.0	16
81	$^{99m}\text{Tc}$ -EDDA/HYNIC-TOC scintigraphy in the differential diagnosis of solitary pulmonary nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1005-1010.	6.4	23
82	Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [ $^{99m}\text{Tc}$ -EDDA-HYNIC-D-Phe <sup>1</sup> , Tyr <sup>3</sup> ]-octreotide, a somatostatin analog for tumor diagnosis. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2497-2506.	3.3	36
83	Clinical usefulness of $^{99m}\text{Tc}$ -EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1402-1406.	6.4	38
84	Theranostic management of medullary thyroid cancer (MTC) with ( $^{111}\text{In}/^{177}\text{Lu}$ ) CP04: how close are we to a clinical solution?. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
85	Six-years experience in the treatment of the neuroendocrine tumors with the use of peptide receptor radionuclide therapy (PRRT). <i>Endocrine Abstracts</i> , 0, , .	0.0	0
86	Patient with dissemination of neuroendocrine neoplasm of unknown origin and carcinoid syndrome: diagnostic and therapeutic difficulties. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
87	$^{99m}\text{Tc}$ -GLP-1 scintigraphy, an efficient method for the detection of insulinoma: results of 3 years' experience. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
88	Combined therapy PRRT with long acting somatostatin analogue: results of 7 years' experience. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
89	Peptide receptor radionuclide therapy as neoadjuvant treatment. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
90	Could $^{99m}\text{Tc}$ labelled glucagon-like peptide 1 analogue scintigraphy be an answer for patients with persistent hypoglycaemia?. <i>Endocrine Abstracts</i> , 0, , .	0.0	0